Avid Bioservices Inc (CDMO)

[Threes]

Bavi's ace in the hole compared to other IO therapy, only Bavi is effective against PD-l and PD-L1 negative tumors.
So the patients that would not respond that have negative PD-1/PD-LI are all ours if Bavi's confirms it is effective.

Should Bavi MOS be equal to other IO treatment, due to the side effects Bavi wins.

President & CEO of Nilogen Oncosystems [=Moffit Startup: http://otmc.moffitt.org/startups.aspx ]. "It is an exciting time for the field of immunotherapy and the data we have been generating support that bavituximab has the potential to activate a tumor specific immune response in patients with PD-L1 negative tumors that generally do not respond as well to PD-1 or PD-L1 inhibitors."


Should a patient as many do only tolerate a single dose of Obdiva, those patients should be given Bavi.

Then of course the combination of the two could become the SOC.

So Doce. future depends on the Sunrise results as well.